Notice of Proposed Sale · 144
Korsana Biosciences, Inc.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- KORSANA BIOSCIENCES, INC.
- Issuer CIK
- 0001755237
- SEC file number
- 001-38787
- Phone
- (781) 516-2325
- Person for whose account securities are to be sold
- ERROL B DE SOUZA
- Relationships to issuer
- Director
- Street
- 203 Crescent Street,
- Street (continued)
- Bldgs. #3/3A/4, Suite 503,
- City
- Waltham
- State / country code
- MA
- Postal code
- 02453
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 4,903 | 171,555.97 | 45,541,425 | 09/23/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2024 | Restricted Stock | Issuer | 4,903 | N | 10/01/2024 | Not Applicable |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| ERROL B DE SOUZA | Common | 09/22/2026 | 100 | 3,499.00 |
| ERROL B DE SOUZA | Common | 09/18/2026 | 2,139 | 74,843.61 |
Seller — prior-sale row 1, entry 1
- Name
- ERROL B DE SOUZA
- Street
- 203 Crescent Street,
- Street (continued)
- Bldgs. #3/3A/4, Suite 503,
- City
- Waltham
- State / country code
- MA
- Postal code
- 02453
Seller — prior-sale row 2, entry 1
- Name
- ERROL B DE SOUZA
- Street
- 203 Crescent Street,
- Street (continued)
- Bldgs. #3/3A/4, Suite 503,
- City
- Waltham
- State / country code
- MA
- Postal code
- 02453
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were acquired upon the vesting of restricted stock during the period of 10/01/2024 through 07/16/26.
Notice signature
- Notice date
- 09/23/2026
- Signed
- /s/ Errol B Desouza
Company context
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com and follow the Company on LinkedIn.
Current securities
Recent company filings
- SCHEDULE 13D - filed by Fairmount Funds Management LLC regarding Korsana Biosciences, Inc.Sep 11, 2026
- Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics · Change in Shell Company Status · Regulation FD DisclosureSep 11, 2026
- 4 filingSep 10, 2026
- 3 filingSep 10, 2026
- 3 filingSep 10, 2026